Ramucirumab in the treatment of gastric cancer
MUDr. Lukáš Chlachula
Onkologické oddělení, Nemocnice Nový Jičín
Gastric cancer is one of the malignancies in the Czech Republic with a declining incidence over time and is the third most common cause of death from oncological diagnosis worldwide. The most common histological subtype is adenocarcinoma. The treatment of gastric adenocarcinomas is always complex, including surgery, chemotherapy, radiotherapy and targeted therapy. Ramucirumab is a monoclonal antibody against vascular endothelial growth factor receptor 2 (VEGFR-2), which blocks the binding of a specific ligand, thereby preventing signal transduction and triggering a signaling pathway leading to tumor neoangiogenesis. Efficacy has been described in two studies - RAINBOW and REGARD.
gastric adenocarcinoma, targeted therapy, ramucirumab, VEGF, VEGFR
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...